Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Glucagon

            Therapeutic Area: Endocrinology Product Name: Ogluo

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 12, 2021

            Details:

            European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Glucagon

            Therapeutic Area: Endocrinology Product Name: Gvoke

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Megapharm

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement December 22, 2020

            Details:

            Megapharm will be responsible for registration and marketing of Gvoke in Israel and the Palestinian Authority, and named patient services supply. Xeris will manufacture, supply, and will take care of the quality assurance and control, regulatory support, and maintenance of IP.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Levothyroxine Sodium

            Therapeutic Area: Endocrinology Product Name: Thyquidity

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Vertice Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement December 17, 2020

            Details:

            Vertice will make a specified quarterly payment to MannKind to defray the costs of the additional promotional activity and will pay MannKind royalties on gross profit resulting from all sales of Thyquidity.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Leuprolide Acetate

            Therapeutic Area: Endocrinology Product Name: Fensolvi

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 24, 2020

            Details:

            The study evaluated 45-mg subcutaneous leuprolide acetate administered at a 6-month interval in 64 GnRHa-naïve children with CPP. Fensolvi effectively suppressed reproductive hormones and stopped or caused regression of pubertal progression.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Insulin Lispro

            Therapeutic Area: Endocrinology Product Name: Lyumjev

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership October 07, 2020

            Details:

            Companies will partner to promote Lyumjev, Lilly's new rapid-acting insulin, with Dexcom G6 Continuous Glucose Monitoring (CGM), highlighting the benefits of using each.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hydrocortisone

            Therapeutic Area: Endocrinology Product Name: Alkindi Sprinkle

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 29, 2020

            Details:

            ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficiency specifically designed for children.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sildenafil Citrate

            Therapeutic Area: Endocrinology Product Name: Viagra

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Farmalider SA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition September 29, 2020

            Details:

            Aspargo’s Sildenafil Oral Spray is an oral liquid suspension of sildenafil citrate administered via a spray pump that dispenses 12.5 mg of sildenafil citrate per push of the pump (referred to as ASP-001) or via an individual single liquid unit dispensing 100 mg per unit.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dulaglutide

            Therapeutic Area: Endocrinology Product Name: Trulicity

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 03, 2020

            Details:

            The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg doses based on data from AWARD-11. The phase 3 trial showed the additional doses led to further benefits in A1C and body weight reduction when compared to Trulicity 1.5 mg.